INSYS Therapeutics, Inc.

Summary of Case:

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into INSYS Therapeutics, Inc. (NASDAQ: INSY) ("Insys") to determine whether the Officers and Directors of Insys have breached their fiduciary duties owed to Insys and its shareholders. Insys investors are encouraged to go to: http://www.scott-scott.com/pop.php?page=join&case_id=2905.  You can also contact Joseph Halloran at (646) 582-0121, or email jhalloran@scott-scott.com for information.

Insys is a specialty pharmaceutical company that develops and commercializes supportive care products.  Insys markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.

On April 24, 2015, after the market close, the Southern Investigating Report Foundation ("SIRF") published an article entitled "Insys Therapeutics and the New ‘Killing It,'" reporting on patients who either died or suffered adverse events while being treated with Subsys. The article also detailed how Insys aggressively markets Subsys.

On this news, the price of Company shares declined $6.00 per share, or nearly 10%,

If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.